Profile data is unavailable for this security.
About the company
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
- Revenue in USD (TTM)544.88m
- Net income in USD-27.71m
- Incorporated1991
- Employees954.00
- LocationLannett Company Inc9000 State RdPHILADELPHIA 19136-1615United StatesUSA
- Phone+1 (215) 333-9000
- Fax+1 (302) 636-5454
- Websitehttps://www.lannett.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals Inc | 15.09m | -102.37m | 263.00m | 172.00 | -- | 17.48 | -- | 17.42 | -3.10 | -3.10 | 0.4195 | 0.3072 | 0.1011 | -- | 2.31 | 74,722.77 | -68.59 | -- | -80.71 | -- | 50.37 | -- | -678.18 | -- | 5.83 | -18.39 | 0.8928 | -- | 10.43 | -- | -109.02 | -- | -- | -- |
| LogicBio Therapeutics Inc | 2.91m | -37.19m | 265.74m | 41.00 | -- | 8.88 | -- | 91.26 | -1.60 | -1.60 | 0.1252 | 0.9411 | 0.0535 | -- | -- | 71,024.39 | -68.30 | -- | -74.85 | -- | -- | -- | -1,276.99 | -- | -- | -55.30 | 0.309 | -- | -- | -- | -127.73 | -- | -- | -- |
| Oncternal Therapeutics Inc | 2.52m | -18.82m | 266.46m | 11.00 | -- | 7.77 | -- | 105.66 | -1.14 | -1.14 | 0.1503 | 0.7026 | 0.1038 | -- | -- | 229,272.70 | -77.46 | -81.90 | -109.83 | -136.40 | -- | -- | -746.39 | -5,751.42 | -- | -- | 0.0188 | -- | -- | -- | 11.01 | -- | -- | -- |
| Tyme Technologies Inc | 0.00 | -28.36m | 266.85m | 18.00 | -- | 18.40 | -- | -- | -0.2333 | -0.2333 | 0.00 | 0.1114 | 0.00 | -- | -- | 0.00 | -142.92 | -- | -192.92 | -- | -- | -- | -- | -- | -- | -13.18 | 0.0119 | -- | -- | -- | 33.30 | -- | -- | -- |
| Gritstone Oncology Inc | 3.57m | -105.85m | 267.15m | 177.00 | -- | 3.35 | -- | 74.77 | -2.87 | -2.87 | 0.0967 | 1.91 | 0.0216 | -- | 23.90 | 20,534.48 | -63.93 | -- | -73.96 | -- | -- | -- | -2,962.52 | -- | -- | -- | 0.00 | -- | 267.73 | -- | -45.79 | -- | -- | -- |
| 9 Meters Biopharma Inc | 0.00 | -65.44m | 267.50m | 8.00 | -- | 54.53 | -- | -- | -0.9605 | -0.9605 | 0.00 | 0.0242 | 0.00 | -- | -- | 0.00 | -551.76 | -306.57 | -26,912.24 | -- | -- | -- | -- | -521.25 | -- | -44.36 | 0.2589 | -- | -- | -- | -11.95 | -- | -- | -- |
| Osmotica Pharmaceuticals PLC | 203.26m | -51.36m | 272.25m | 379.00 | -- | 1.82 | -- | 1.34 | -0.924 | -0.924 | 3.51 | 2.39 | 0.4412 | 3.26 | 7.33 | 536,314.20 | -11.15 | -- | -13.04 | -- | 60.75 | -- | -25.27 | -- | 2.81 | 1.06 | 0.5928 | -- | -8.98 | -- | -146.99 | -- | -- | -- |
| Lannett Company, Inc. | 544.88m | -27.71m | 279.39m | 954.00 | -- | 0.8818 | 9.24 | 0.5128 | -0.72 | -0.72 | 13.87 | 7.60 | 0.473 | 2.60 | 3.49 | 571,154.10 | -2.41 | -3.22 | -2.91 | -3.77 | 27.21 | 42.50 | -5.09 | -7.25 | 1.30 | 0.776 | 0.6904 | -- | -16.73 | 6.05 | 87.74 | -- | 8.07 | -- |
| Vyne Therapeutics Inc | 16.71m | -253.89m | 280.36m | 180.00 | -- | 5.66 | -- | 16.78 | -3.19 | -3.19 | 0.1791 | 0.295 | 0.1636 | -- | -- | 417,675.00 | -248.59 | -- | -295.88 | -- | 94.86 | -- | -1,519.63 | -- | 3.95 | -154.14 | 0.40 | -- | -100.00 | -- | -43.27 | -- | -- | -- |
| RenovaCare Inc | 0.00 | -8.18m | 280.97m | 2.00 | -- | 32.71 | -- | -- | -0.0936 | -0.0936 | 0.00 | 0.0983 | 0.00 | -- | -- | 0.00 | -71.06 | -47.25 | -75.13 | -50.26 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -58.34 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 0.00 | -37.35m | 281.68m | 17.00 | -- | 7.19 | -- | -- | -1.50 | -1.50 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -47.89 | -- | -66.30 | -- | -- | -- | -- | -- | -- | -29.74 | 0.4717 | -- | -- | -- | -36.61 | -- | -- | -- |
| CorMedix Inc. | 208.29k | -21.24m | 284.05m | 30.00 | -- | 8.04 | -- | 1,363.73 | -0.7875 | -0.7875 | 0.0078 | 1.10 | 0.0057 | 0.666 | 41.33 | 6,943.00 | -57.62 | -109.70 | -66.25 | -142.18 | 6.99 | -6.35 | -10,199.69 | -8,065.86 | 8.40 | -- | 0.00 | -- | -34.09 | 8.40 | -62.27 | -- | 7.56 | -- |
| Checkmate Pharmaceuticals Inc | -100.00bn | -100.00bn | 285.33m | 22.00 | -- | 2.11 | -- | -- | -- | -- | -- | 6.27 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.48 | -- | -- | -- |
| Chromadex Corp | 56.90m | -22.68m | 288.55m | 110.00 | -- | 14.76 | -- | 5.07 | -0.3763 | -0.3763 | 0.9403 | 0.3164 | 1.41 | 2.26 | 17.90 | 517,281.80 | -56.31 | -52.15 | -80.26 | -74.63 | 58.55 | 49.87 | -39.86 | -61.88 | 1.51 | -471.52 | 0.0054 | -- | 46.69 | 24.76 | 3.51 | -- | 24.37 | -- |
| Vincerx Pharma Inc | -100.00bn | -100.00bn | 293.67m | -- | -- | 2.75 | -- | -- | -- | -- | -- | 7.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0157 | -- | -- | -- | -8,144.14 | -- | -- | -- |
Data as of Jan 15 2021. Currency figures normalised to Lannett Company Inc's reporting currency: US Dollar USD
61.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Telemus Capital LLCas of 30 Sep 2020 | 7.69m | 18.45% |
| BlackRock Fund Advisorsas of 30 Sep 2020 | 4.78m | 11.46% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2020 | 2.71m | 6.50% |
| The Vanguard Group, Inc.as of 30 Sep 2020 | 2.22m | 5.33% |
| LSV Asset Managementas of 30 Sep 2020 | 2.01m | 4.82% |
| D. E. Shaw & Co. LPas of 30 Sep 2020 | 1.80m | 4.32% |
| Renaissance Technologies LLCas of 30 Sep 2020 | 1.70m | 4.07% |
| SSgA Funds Management, Inc.as of 30 Sep 2020 | 1.29m | 3.09% |
| Dimensional Fund Advisors LPas of 30 Sep 2020 | 949.73k | 2.28% |
| JPMorgan Chase Bank, NA (Investment Management)as of 30 Sep 2020 | 617.32k | 1.48% |
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
